Front Page
- Covaxin shows 81% efficacy, also works against variants (GS-2)
- U.S. thinktank report classifies India as ‘partly free’ (GS-2)
- Voicing dissent against govt. is not sedition: SC (GS-2)
Business
World
- At least 38 protesters killed in Myanmar (GS-2)
- India, 17 countries face U.S. anti-dumping tax (GS-2)
- Blinken calls China the ‘biggest geopolitical test’ for U.S. (GS-2)
News
- Vaccine can be taken 24/7, says Centre (GS-2)
- Six States continue to see a rise in COVID-19 numbers (GS-2)
- ‘Vaccine lifts antibody level in 14 days’ (GS-2)
- ‘Linguistic barriers to education must go’ (GS-2)
- India is ‘partly free’, says U.S. thinktank (GS-2)
- Field trials for Census-NPR to begin soon (GS-1)
- 14 Trojans found in servers, says Minister (Prelims)
- Covaxin efficacy is 81%, works against variants
- Voicing dissent against govt. is not sedition: SC
OPED
Editorial